

IN SESSION WITH JOHN EIKELBOOM & ERIK GROVE

FROKOSTSYMPOSIUM VED DCS ÅRSMØDE
Hotel Nyborg Strand
Fredag d. 4 maj 12.30 - 13.30

WHAT ARE THE ISSUES IN 2018?

OAC for stroke prevention in atrial fibrillation

Welcome and introduction

Chairman: Erik Grove

Associate Professor, MD, PhD Department of Cardiology, Aarhus University Hospital, Skejby Denmark

Speaker: John Eikelboom

Associate Professor, Department of Medicine, McMaster University, Division of Hematology & Thromboembolism, Hamilton General Hospital, Ontario Canada

- **BLEEDING RISK AS A BARRIER TO TREATMENT**
- **RECENT DEVELOPMENTS IN ANTICOAGULANT THERAPY**
- **MAKING THE RIGHT CHOICES IN 2018**



BIOGRAPHY JOHN EIKELBOOM, MBBS, MSC, FRCPC

Prof. John Eikelboom originally trained in Internal Medicine and Haematology in Perth, Australia and subsequently moved to Hamilton to take up a Tier II Canada Research Chair in Cardiovascular Medicine. He has co-authored more than 500 articles in peer-reviewed journals. His current research, supported by the Canadian Institutes for Health Research, the Heart and Stroke Foundation and the National Health and Medical Research Council of Australia, focuses on the efficacy and safety of antithrombotic therapies, outcomes after blood transfusion and bleeding, and the mechanisms of variable response to antiplatelet drugs.

Dette frokostsymposium er ikke en del af DCS årsmøde, men er arrangeret og sponsoreret af Boehringer Ingelheim. Vi gør opmærksom på, at Boehringer Ingelheim Danmark A/S har anmeldt arrangementet til ENLI (Ethisk Nævn for Lægemiddelindustrien). Arrangementet er, efter vores opfattelse, i overensstemmelse med reglerne på området, selvom arrangementet ikke på forhånd er godkendt af ENLI.

